Matching-Adjusted Indirect Treatment Comparison of Sotorasib vs Adagrasib for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (20240246)

Study identification

• EU PAS number:
  EUPAS1000000380
• Study ID:
  1000000380
• Official title and acronym:
  Matching-Adjusted Indirect Treatment Comparison of Sotorasib vs Adagrasib for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (20240246)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen Inc.

Study timelines

Date when funding contract was signed

Planned:15/09/2024

Actual:24/09/2024

Study start date

Planned:29/11/2024

Actual:26/11/2024

Data analysis start date

Planned:29/11/2024

Actual:26/11/2024

Date of interim report, if expected

Planned:31/12/2024

Date of final study report

Planned:30/09/2025

Actual:23/10/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

This study is being funded by Amgen Inc.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable